The cleverer I am about miniaturizing the world, the better I am at possessing it.” That line of thinking, as practiced in nanoscale engineering, has no stronger embodiment today than ChemLex’s newly ...

The status could support staged transitions to new manufacturing processes, potentially mitigating some risks of high-stakes ...

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug. At the heart of the deal is brelovitug, an immunoglobulin G1 monoclonal ...

Kymera shows strong KT-621 Phase 1b efficacy, solid safety, platform validation, cash runway and growth potential in key ...

As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a ...

An internal memo written by the Food and Drug Administration's top vaccine regulator offers a concerning glimpse into the future of vaccine regulation in the US -- and could have profound implications ...

Vinay Prasad’s memo makes alarming claims about the COVID-19 vaccine — including the assertion, made without any supporting ...

Fourteen graduates got their records expunged for completing the (W)RAP program, which offers non-violent offenders treatment ...

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.